A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer

BACKGROUND AND OBJECTIVE: Previous studies have demonstrated that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are able to effectively improve the prognosis of hormone receptor positive (HR(+)), human epidermal growth factor receptor 2 (HER2) negative advanced brea...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shidi, Zhang, Haochen, Yang, Na, Yang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331716/
https://www.ncbi.nlm.nih.gov/pubmed/37434680
http://dx.doi.org/10.21037/tcr-22-2807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331716/
https://www.ncbi.nlm.nih.gov/pubmed/37434680
http://dx.doi.org/10.21037/tcr-22-2807

Ejemplares similares